Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - NYSE Other stock markets 04:03:16 2026-06-29 pm EDT			After hours 08:00:00 pm
129.38 ^USD	+0.56%		126.00	-2.61%

Jun. 29	Scotiabank Raises Merck Price Target to $155 From $136, Sector Outperform Rating Kept	MT
Jun. 29	Merck & Co., Inc. Enters Agreement With ADAP Crisis Task Force To Provide Access To IDVYNSO (Doravirine/Islatravir) For Eligible Individuals	CI

Merck Nearing Around $6 Billion Deal to Buy Terns Pharma, FT Says, Citing Sources

Published on 03/24/2026 at 09:52 pm EDT - Modified on 03/24/2026 at 09:53 pm EDT

Dow Jones

MERCK & CO., INC.

+0.56%

TERNS PHARMACEUTICALS, INC.

+0.04%

--Merck & Co. is nearing a deal valued at around $6 billion to acquire Terns Pharma, a U.S. biotech company that develops treatments for a form of blood and bone cancer, Financial Times reports, citing people familiar with the matter.

--Talks between the two entities are at an advanced stage and a deal could be reached in coming days, FT says, citing people.

--Merck and Terns didn't immediately respond to requests for comment, the report says.

Full story: https://www.ft.com/content/3f695210-8cc0-4736-837a-7961d80588d9?syn-25a6b1a6=1

Write to Megan Cheah at megan.cheah@wsj.com

(END) Dow Jones Newswires

03-24-26 2151ET

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Off-Hours Price	Change	5-day change	Capi.
	MERCK & CO., INC.	129.38USD	+0.56%	+12.04%	320B
	TERNS PHARMACEUTICALS, INC.	52.95USD	+0.04%	-.--%	6.11B

Latest news about Merck & Co., Inc.

Jun. 29	Scotiabank Raises Merck Price Target to $155 From $136, Sector Outperform Rating Kept	MT
Jun. 29	Merck & Co., Inc. Enters Agreement With ADAP Crisis Task Force To Provide Access To IDVYNSO (Doravirine/Islatravir) For Eligible Individuals	CI
Jun. 29	Merck Agrees With ADAP Crisis Task Force to Provide Access to HIV Treatment Idvynso	MT
Jun. 25	Merck Gains FDA Approval for Keytruda Plus Trodelvy in PD-L1 Positive Breast Cancer	MT
Jun. 25	Alerts incorrectly tagged to Merck & Co withdrawn	RE
Jun. 25	Merck & Co., Inc. Announces FDA Approval Of KEYTRUDA (Pembrolizumab) And KEYTRUDA QLEX (Pembrolizumab And Berahyaluronidase Alfa-Pmph), Each In Combination With Gilead Sciences, Inc.'s Trodelvy (Sacituzumab Govitecan-Hziy) As First-Line Treatment Of PD-L1+ (CPS =10) Advanced Triple-Negative Breast Cancer	CI
Jun. 25	Major deals involving US drugmakers and biotechs over the past decade	RE
Jun. 25	Merck Reviews Regional Distribution Hub Plan In Abu Dhabi	MT
Jun. 25	Merck & Co., Abu Dhabi's Department of Health Partner to Evaluate New Logistics Hub in UAE	MT
Jun. 24	Gilead Says FDA Approves Trodelvy for First-Line Treatment of Advanced Triple-Negative Breast Cancer	MT
Jun. 24	Merck Receives European Commission Approval For KEYTRUDA Plus Padcev as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen For Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer	CI
Jun. 24	Merck & Co.'s Keytruda Combination Treatment for Bladder Cancer Gets EU Approval	MT
Jun. 24	Merck Wins European Commission Approval for KEYTRUDA Plus Padcev in Bladder Cancer	MT
Jun. 24	CICC Research Initiates Coverage on Merck With Outperform Rating, $138 Price Target	MT
Jun. 24	CICC Initiates Merck & Co. at Outperform With $138 Price Target	MT

Chart Merck & Co., Inc.

Duration

Period

MRK: Dynamic Chart

Company Profile

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (73.9%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (15.5%); - sale of animal health products (9.8%); - other (0.8%). Net sales are distributed geographically as follows: the United States (56.2%), Europe/Middle East/Africa (22.4%), Latin America (5.2%), Asia/Pacific (4.6%), Japan (4.2%), China (3%) and other (4.4%).

Employees

74,000

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company